Literature DB >> 16818744

Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.

Andrew G Jarnicki1, Joanne Lysaght, Stephen Todryk, Kingston H G Mills.   

Abstract

We examined the hypothesis that a failure of the immune system to eradicate tumors is due to the immunosuppressive environment created by the growing tumor, which is influenced by the site of tumor growth. We demonstrated that T cell responses to a bystander Ag in mice were suppressed by a growing CT26 tumor. T cells purified from the growing tumor expressed mRNA for IL-10, TGF-beta, and Foxp3. Intracellular cytokine staining revealed a high frequency of IL-10-secreting macrophages, dendritic cells, and CD4+ and CD8+ T cells infiltrating the tumor. In contrast, T cell IFN-gamma production was weak and CD8+ CTL responses were undetectable in mice with CT26 lung metastases and weak and transient following s.c. injection of CT26 cells, but were enhanced in the presence of anti-IL-10 and anti-TGF-beta. Consistent with this, removal of CD8+ T cells abrogated CTL responses and promoted progression of the s.c. tumor. However, in the lung model, depletion of CD8+ T cells significantly reduced the tumor burden. Furthermore, depletion of CD4+ or CD25+ T cells in vivo reduced tumor burden in s.c. and lung models, and this was associated with significantly enhanced IFN-gamma production by CD8+ T cells. These findings suggest that tumor growth facilitates the induction or recruitment of CD4+ regulatory T cells that secrete IL-10 and TGF-beta and suppress effector CD8+ T cell responses. However, CD8+ T regulatory cells expressing IL-10 and TGF-beta are also recruited or activated by the immunosuppressive environment of the lung, where they may suppress the induction of antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818744     DOI: 10.4049/jimmunol.177.2.896

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  140 in total

1.  Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Authors:  Keith L Knutson; Matthew J Maurer; Claudia C Preston; Kirsten B Moysich; Krista Goergen; Kieran M Hawthorne; Julie M Cunningham; Kunle Odunsi; Lynn C Hartmann; Kimberly R Kalli; Ann L Oberg; Ellen L Goode
Journal:  Cancer Immunol Immunother       Date:  2015-08-23       Impact factor: 6.968

Review 2.  Emerging concepts in CD8(+) T regulatory cells.

Authors:  Jerry Y Niederkorn
Journal:  Curr Opin Immunol       Date:  2008-04-10       Impact factor: 7.486

3.  Activation outcomes induced in naïve CD8 T-cells by macrophages primed via "phagocytic" and nonphagocytic pathways.

Authors:  Isabel María Olazabal; Noa Beatriz Martín-Cofreces; María Mittelbrunn; Gloria Martínez del Hoyo; Balbino Alarcón; Francisco Sánchez-Madrid
Journal:  Mol Biol Cell       Date:  2007-12-12       Impact factor: 4.138

Review 4.  The opposing roles of CD4+ T cells in anti-tumour immunity.

Authors:  Tomasz Ahrends; Jannie Borst
Journal:  Immunology       Date:  2018-04-27       Impact factor: 7.397

5.  Melanoma induces immunosuppression by up-regulating FOXP3(+) regulatory T cells.

Authors:  Joel Baumgartner; Cara Wilson; Brent Palmer; Don Richter; Anirban Banerjee; Martin McCarter
Journal:  J Surg Res       Date:  2007-07       Impact factor: 2.192

6.  PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Authors:  Hyun-Bae Jie; Yu Lei; Jing Li; Neil Gildener-Leapman; Sumita Trivedi; Tony Green; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

9.  Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.

Authors:  Zhuangwei Lv; Min Liu; Jinghui Shen; Dong Xiang; Yunfeng Ma; Yanhong Ji
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

Review 10.  The dual role of complement in cancer and its implication in anti-tumor therapy.

Authors:  Ioannis Kourtzelis; Stavros Rafail
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.